25,654 Shares in Globus Medical, Inc. $GMED Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new position in Globus Medical, Inc. (NYSE:GMED) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 25,654 shares of the medical device company’s stock, valued at approximately $2,254,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Rockefeller Capital Management L.P. boosted its position in shares of Globus Medical by 52.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,738 shares of the medical device company’s stock valued at $1,025,000 after acquiring an additional 4,042 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of Globus Medical by 7.1% in the fourth quarter. Corient Private Wealth LLC now owns 51,372 shares of the medical device company’s stock worth $4,487,000 after purchasing an additional 3,390 shares during the last quarter. MidFirst Bank bought a new position in shares of Globus Medical in the fourth quarter worth approximately $354,000. Pacer Advisors Inc. raised its stake in Globus Medical by 20.4% in the fourth quarter. Pacer Advisors Inc. now owns 33,177 shares of the medical device company’s stock valued at $2,897,000 after purchasing an additional 5,617 shares in the last quarter. Finally, Kera Capital Partners Inc. purchased a new stake in Globus Medical in the fourth quarter valued at approximately $202,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

NYSE:GMED opened at $78.18 on Friday. The business has a 50 day moving average of $80.65 and a 200 day moving average of $86.83. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 1.58 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the firm earned $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current year.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

GMED has been the subject of several research analyst reports. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Stifel Nicolaus decreased their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday. Wells Fargo & Company lowered their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. BMO Capital Markets began coverage on shares of Globus Medical in a report on Wednesday. They set an “outperform” rating and a $94.00 price objective for the company. Finally, Piper Sandler cut their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $105.42.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.